REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc., trading under the ticker REVB on Nasdaq, is a clinical-stage biopharmaceutical company that completed its business combination with Chardan NexTech Acquisition 2 Corp, a special purpose acquisition company sponsored by an affiliate of Chardan Capital Markets that completed its IPO in 2021. The merger brought Revelation Biosciences into the public markets within the life sciences and biotechnology sector, where the company focuses on immune system modulation and adjuvant-based therapeutic development. The company filed its annual 10-K report with the SEC on April 15, 2022, covering fiscal year 2021 operations as a newly combined public entity. For comprehensive filing history, merger terms, sponsor details, and current trading data on REVB and hundreds of other SPAC transactions, sign up for full access at SpacDesk.